Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...
The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...
Investigators evaluated children with acute lymphoblastic or acute myeloid leukemia to identify racial/ethnic and neighborhood disparities in acute kidney injury.
Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results